Literature DB >> 8489109

Serologic evidence of previous Campylobacter jejuni infection in patients with the Guillain-Barré syndrome.

B Mishu1, A A Ilyas, C L Koski, F Vriesendorp, S D Cook, F A Mithen, M J Blaser.   

Abstract

OBJECTIVE: To determine if patients with the Guillain-Barré syndrome are likely to have had Campylobacter jejuni infection before onset of neurologic symptoms.
DESIGN: A case-control study.
SETTING: Several university medical centers. PATIENTS: Case patients met clinical criteria for the Guillain-Barré syndrome between 1983 and 1990 and had a serum sample collected and frozen within 3 weeks after onset of neurologic symptoms (n = 118). Disease controls were patients with other neurologic illnesses (n = 56); healthy controls were hospital employees or healthy family members of patients (n = 47). MEASUREMENTS: Serum IgA, IgG, and IgM antibodies to C. jejuni were determined by enzyme-linked immunosorbent assays. Assays were done in a blinded manner.
RESULTS: Optical density ratios > or = 2 in two or more immunoglobulin classes were seen in 43 (36%) of patients with the Guillain-Barré syndrome and in 10 (10%) of controls (odds ratio, 5.3; 95% CI, 2.4 to 12.5; P < 0.001). Increasing the optical density ratio or the number of immunoglobulin classes necessary to yield a positive result increased the strength of the association. The number of patients with the Guillain-Barré syndrome who had positive serologic responses was greatest from September to November (P = 0.02). Male patients were three times more likely to have serologic evidence of C. jejuni infection (P = 0.009); the proportion of patients with the syndrome who had a positive serologic response increased with age.
CONCLUSIONS: Patients with the Guillain-Barré syndrome are more likely than controls to have serologic evidence of C. jejuni infection in the weeks before onset of neurologic symptoms. Campylobacter jejuni may play a role in the initiation of the Guillain-Barré syndrome in many patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8489109     DOI: 10.7326/0003-4819-118-12-199306150-00006

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  31 in total

Review 1.  Guillain-Barré syndrome.

Authors:  U Seneviratne
Journal:  Postgrad Med J       Date:  2000-12       Impact factor: 2.401

Review 2.  Guillain Barré syndrome.

Authors:  J B Winer
Journal:  Mol Pathol       Date:  2001-12

3.  Serological Markers of Recent Campylobacter jejuni Infection in Patients with Guillain-Barré Syndrome in the State of Piauí, Brazil, 2014-2016.

Authors:  Cintya O Souza; Marcelo A C S Vieira; Francisca M A Batista; Kelsen D Eulálio; Jéssica M M Neves; Laís C Sá; Leni C R Monteiro; Walfrido S Almeida-Neto; Raimunda S S Azevedo; Dorcas L Costa; Ana C R Cruz
Journal:  Am J Trop Med Hyg       Date:  2018-01-04       Impact factor: 2.345

4.  Epidemiology of peripheral neuropathy.

Authors:  C N Martyn; R A Hughes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-04       Impact factor: 10.154

Review 5.  Emerging foodborne diseases.

Authors:  S F Altekruse; M L Cohen; D L Swerdlow
Journal:  Emerg Infect Dis       Date:  1997 Jul-Sep       Impact factor: 6.883

6.  Peripheral nervous system manifestations of infectious diseases.

Authors:  Kate T Brizzi; Jennifer L Lyons
Journal:  Neurohospitalist       Date:  2014-10

7.  Improved serological diagnosis stresses the major role of Campylobacter jejuni in triggering Guillain-Barré syndrome.

Authors:  Ruprecht Schmidt-Ott; Holger Schmidt; Sylvia Feldmann; Felicitas Brass; Bernd Krone; Uwe Gross
Journal:  Clin Vaccine Immunol       Date:  2006-07

8.  Electrophysiological studies in Guillain-Barré syndrome: correlation with antibodies to GM1, GD1B and Campylobacter jejuni.

Authors:  F J Vriesendorp; W J Triggs; R F Mayer; C L Koski
Journal:  J Neurol       Date:  1995-07       Impact factor: 4.849

Review 9.  Quantifying the association between Campylobacter infection and Guillain-Barré syndrome: a systematic review.

Authors:  Kate O Poropatich; Christa L Fischer Walker; Robert E Black
Journal:  J Health Popul Nutr       Date:  2010-12       Impact factor: 2.000

10.  Experimental immunization with Borrelia burgdorferi induces development of antibodies to gangliosides.

Authors:  J C Garcia-Monco; R J Seidman; J L Benach
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.